Cancer of Pancreas

Groupe Hospitalier Paris Saint-Joseph

Evaluation of the FOCUS Diffusion's Added Clinical Value Compared to Conventional MRI

Evaluation of the FOCUS Diffusion's Added Clinical Value Compared to Conventional MRI With Wide Field View Diffusion in Focal Pancreatic Lesions Characterization

Diagnostic accuracy difference between the standard protocol and the combined protocol.

Differences between the standard protocol and the combined protocol in terms of sensitivity and specificity in the diagnosis of benign or malignant tumors.

Confidence scores assigned by radiologist

Differences between the FOCUS diffusion sequence and the "wide field" sequence in terms of lesions' detected number

Differences between the FOCUS diffusion sequence and the "wide field" sequence in terms of image quality

Groupe Hospitalier Paris Saint Joseph

GTX - A two week regimen of Gemcitabine at 600 mg/m2 on days 4 and 1, infused over 60 minutes, Docetaxel at 30 mg/m2 on days 4 and 11, infused over 60 minutes and Capecitabine at 1000 mg/m2 (capped at 1000 mg BID days 1-14) followed by one week off for a total of a 21 day cycle. This is repeated for a total of 6 months.

Gemcitabine, Docetaxel, Capecitabine GTX

Age, Customized

Sex: Female, Male

Ethnicity (NIH/OMB)

Race (NIH/OMB)

Safety of the GTX regimen in patients with resected pancreatic cancer, using the NCI Common Terminology Criteria for Adverse Events (CTCAE) Version 3.0.
Data was not analyzed because original PI left institution before data analysis was completed.

Number of Subjects Who Experience Dose Limiting Toxicities (DLTs)

Median recurrence free survival in patients with non-metastatic, resected pancreatic cancer treated with adjuvant GTX.
Data was not analyzed because original PI left institution before data analysis was completed.

Time to Death

Quality of life score of patients treated with the adjuvant GTX regimen using, the FACT-Hep (Version 4), a sensitive measure of quality of life.
Data was not analyzed because original PI left institution before data analysis was completed.

Score on FACT-Hep (Version 4)

Overall Study

Paul Oberstein, MD

GTX - A two week regimen of Gemcitabine at 600 mg/m2 on days 4 and 1, infused over 60 minutes, Docetaxel at 30 mg/m2 on days 4 and 11, infused over 60 minutes and Capecitabine at 1000 mg/m2 (capped at 1000 mg BID days 1-14) followed by one week off for a total of a 21 day cycle. This is repeated for a total of 6 months.
AE data was collected on 26 subjects (out of 37 subjects, 10 were screen failures and 1 was not treated).

Pancreatic Cancer

Days 4 and 11: gemcitabine 600 mg/m2 over 60 mins intravenous (IV) followed by docetaxel 30 mg/m2 over 60 mins IV

Gemcitabine

Docetaxel

Day 1-14: capecitabine at 1000 mg/m2/day divided into 2 doses given two times a day (BID) by mouth (PO) Maximum dose 2000mg/day divided into BID dosing

pancreatic neoplasms/edema

Evaluation of the FOCUS Diffusion's Added Clinical Value Compared to Conventional MRI

A Study of Gemzar, Taxotere, and Xeloda for Adjuvant Pancreatic Cancer

Najkompletnija baza ljekovitog bilja potpomognuta naukom